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Attenuated Virulence and Biofilm Formation in Staphylococcus aureus
following Sublethal Exposure to Triclosan
Joe Latimer, Sarah Forbes, and Andrew J. McBain
School of Pharmacy and Pharmaceutical Sciences, The University of Manchester, Manchester, United Kingdom
Subeffective exposure of Staphylococcus aureus to the biocide triclosan can reportedly induce a small-colony variant (SCV) phe-
notype. S. aureus SCVs are characterized by low growth rates, reduced pigmentation, and lowered antimicrobial susceptibility.
While they may exhibit enhanced intracellular survival, there are conflicting reports regarding their pathogenicity. The current
study reports the characteristics of an SCV-like strain of S. aureus created by repeated passage on sublethal triclosan concentra-
tions. S. aureus ATCC 6538 (the passage 0 [P0] strain) was serially exposed 10 times to concentration gradients of triclosan to
generate strain P10. This strain was then further passaged 10 times on triclosan-free medium (designated strain 10). The MICs
and minimum bactericidal concentrations of triclosan for P0, P10, and 10 were determined, and growth rates in biofilm and
planktonic cultures were measured. Hemolysin, DNase, and coagulase activities were measured, and virulence was determined
using a Galleria mellonella pathogenicity model. Strain P10 exhibited decreased susceptibility to triclosan and characteristics of
an SCV phenotype, including a considerably reduced growth rate and the formation of pinpoint colonies. However, this strain
also had delayed coagulase production, had impaired hemolysis (P < 0.01), was defective in biofilm formation and DNase activ-
ity, and displayed significantly attenuated virulence. Colony size, hemolysis, coagulase activity, and virulence were only partially
restored in strain 10, whereas the planktonic growth rate was fully restored. However, 10 was at least as defective in biofilm
formation and DNase production as P10. These data suggest that although repeated exposure to triclosan may result in an SCV-
like phenotype, this is not necessarily associated with increased virulence and adapted bacteria may exhibit other functional
deficiencies.
S
taphylococcus aureus is an important human pathogen that is
responsible for a range of hospital and community-acquired
infections (10, 15). Successful treatment of such infections is com-
plicated not only by the emergence of methicillin-resistant S. au-
reus (MRSA) strains (10) but also, it has been claimed, by the
spontaneous generation of small-colony variants (SCVs) (55).
S. aureus SCVs are slow growing subpopulations that may be
recovered from patients with persisting or relapsing infections
(44), particularly those undergoing treatment with aminoglyco-
side antibiotics (13), which exhibit decreased susceptibility to an-
timicrobials. SCVs display a distinct phenotype, characterized by
the formation of pinpoint colonies on agar, low growth rate, and
reduced pigmentation. Such characteristics may lead to their mis-
identification in the hospital laboratory (28), potentially compli-
cating diagnosis (43).
The SCV phenotype has commonly been attributed to defects
in the electron transport chain due to mutations in hemB, ctaA, or
menD, which inhibit hemin, hemin A, and menadione biosynthe-
sis, respectively (14, 54). Some SCVs result from thymidine aux-
otrophy, due to mutations in genes encoding thymidine synthesis
or transport (9). Such SCVs can survive on exogenous thymidine,
for instance, in the airway secretions of patients with cystic fibro-
sis, which are rich in necrotic cells (9, 24, 25). Thymidine is also
required for menadione biosynthesis, suggesting that menadione
auxotrophy may be a common factor in SCV formation in men-
adione and thymidine mutants. However, SCVs isolated from in-
fections can result from mechanisms other than menadione and
thymidine auxotrophy (47), suggesting a diversity in SCV mech-
anisms that has not been systematically investigated and that SCVs
which emerge from various sources are not necessarily function-
ally equivalent.
Reduced susceptibility to antibiotics in SCVs is likely to be
multifactorial, depending on whether the particular SCV is attrib-
utable to aminoglycoside-selected auxotrophy or was generated
by other means, since electron transport chain defects result in
reduced electrochemical gradients which may impair the uptake
of aminoglycosides and other cationic molecules (4, 37). Addi-
tionally, the lowered growth rate in SCVs could reduce antimicro-
bial susceptibility by nonspecific mechanisms associated with re-
duced expression of pharmacological targets. Alternatively,
enhanced survival within the host cells could shield the bacteria
from inhibitory concentrations of antibiotics and biocides. The
clinical significance of this, however, depends on whether SCVs
can revert to full virulence following cessation of treatment (37)
and on whether the expression of SCV phenotypes influences the
ability to form recalcitrant biofilms on surfaces.
The generation of the SCV phenotype in S. aureus has report-
edly been induced in vitro by exposure to triclosan (7, 49), a tri-
chlorinated diphenyl ether biocide. Effective concentrations of
triclosan are highly bactericidal toward susceptible species, where
the molecule causes membrane damage through direct interac-
tion and by perturbing lipid biosynthesis (36, 46, 53). Triclosan is
used as an antibacterial in a variety of consumer and clinical ap-
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plications (5, 12, 16), including triclosan wash solutions, which
have been used to reduce carriage of MRSA in hospitals (2, 26, 45,
56). The enoyl-acyl carrier protein reductase FabI has been iden-
tified to be a primary pharmacological target (31, 36) for triclosan.
Inhibition renders the cell unable to synthesize fatty acids and
growth is therefore inhibited, and depending on concentration
and time, bacteria can be permanently inactivated (21). Concern
has been expressed that the use of triclosan and other antiseptics
should be limited to applications where a clear health benefit can
be demonstrated, due to the possibility of reduced susceptibility to
the molecule and potentially also to chemically unrelated com-
pounds (18).
Reduced susceptibility to triclosan has been shown in a num-
ber of in vitro studies but not, to date, in the environment (32, 38).
In one study, SCVs generated by the in vitro exposure of bacteria
to sublethal concentrations of triclosan impregnated in silicone
disks exhibited reduced susceptibility to the molecule and altered
colony morphology (7). Since triclosan-exposed S. aureus has the
potential to display an SCV-like phenotype and some clinical SCV
isolates appear to be able to cause disease (49), it has been inferred
that triclosan use might generate SCVs, which could potentially be
of clinical significance (7). However, these in vitro studies do not
necessarily reflect the clinical impact of triclosan-selected SCVs
(48). For example, in a previously reported study, SCVs generated
using triclosan-impregnated disks demonstrated a low growth
rate, reduced coagulase and DNase activity, and decreased hemo-
lysis (7), which are suggestive of decreased virulence.
There is a clear need to determine the ability of triclosan-gen-
erated SCVs to initiate infection (48). To our knowledge, there are
currently no published reports regarding the impact of triclosan
exposure on the pathogenic capability of resulting SCV-like
strains. Additionally, while antibiotic-selected SCVs may revert to
wild-type phenotype in vivo following cessation of treatment, this
has not been reported for triclosan-selected SCVs. The present
study therefore investigates the growth and virulence of an SCV-
like S. aureus strain created by serial exposure to subinhibitory
concentrations of triclosan. The potential reversion of this strain
following subsequent repeated passage on triclosan-free medium
was also studied.
MATERIALS AND METHODS
Bacterial strains and growth media. Staphylococcus aureus ATCC 6538
was acquired from the American Type Culture Collection and cultured on
Mueller-Hinton agar (MHA), Colombia blood agar (CBA), or mannitol
salt agar (MSA) (Oxoid, United Kingdom) aerobically at 37°C. For sup-
plementation experiments, hemin (final concentration, 1, 10, or 100 M),
menadione (final concentration, 0.4, 4, or 40 M), or thymidine (final
concentration, 0.62, 6.2, or 62 M) was added to MHA. Cryogenic stocks
of the bacteria were archived at 80°C.
Selection of isolates with reduced susceptibility to triclosan. Repro-
ducible concentration gradients of triclosan were created on Mueller-
Hinton agar by depositing stock solutions of triclosan (100 g/ml or 1
mg/ml) with a Wasp II spiral plater (Don Whitley, Shipley, United King-
dom) (30, 35). Plates were dried for 1 h at room temperature prior to
radial deposition of an overnight suspension of S. aureus and incubated
for 4 days aerobically at 37°C. Growth observed at the highest triclosan
concentration was aseptically removed and used to inoculate further gra-
dient plates. This process was repeated for 10 passages. A further 10 pas-
sages were performed on triclosan-free MHA. Wild-type bacteria (the
passage 0 [P0] strain), those passaged 10 times on triclosan (strain P10),
and those passaged a further 10 times on triclosan-free MHA (strain 10)
were archived at 80°C for subsequent MIC and MBC determination.
Determination of bacterial MICs. Overnight cultures of S. aureus
were diluted 1:100 in sterile Mueller-Hinton broth (MHB), and aliquots
(120 l) were delivered to wells of polystyrene 96-well plates (Corning
Ltd., Corning, NY). Stock solutions (1.16 mg/ml) of triclosan were pre-
pared in 25% ethanol, filter sterilized, and stored at 80°C. Doubling
dilutions of triclosan were added to the diluted overnight cultures (final
concentrations, 232 g/ml to 0.23 g/ml). Sterile and triclosan-free con-
trols were also included. Plates were incubated for 24 h aerobically at 37°C
with shaking at 100 rpm. MICs were determined as the lowest concentra-
tion of triclosan showing no turbidity in comparison to a sterile negative
control. Three technical and two biological replicates were conducted.
Previous validation studies with staphylococci and other genera showed
that the triclosan solvent has no effect on the outcome of MIC or mini-
mum bactericidal concentration (MBC) determinations (30).
Determination of bacterial MBCs. Aliquots (10 l) taken from MIC
plates (see above) were spot plated onto MHA in triplicate and incubated
aerobically at 37°C. MBCs were determined as the lowest concentration of
triclosan at which no growth was observed after 4 days of incubation.
Planktonic growth rate measurement. Overnight suspensions of S.
aureus P0, P10, and 10 were diluted 1:100 in MHB (30 ml) and incu-
bated at 37°C with shaking at 150 rpm. Samples were regularly removed
and diluted as appropriate. Optical density was measured at 630 nm using
a Helios spectrophotometer (Pye Unicam Ltd., Cambridge, United King-
dom).
Determination of biofilm growth rates. Overnight suspensions of S.
aureus P0, P10, and 10 were diluted 1 in 40 in MHB, and aliquots (200
l) were delivered to wells of polystyrene 96-well plates. Sterile controls
were also included. Plates were incubated statically aerobically or in an
anaerobic workstation (Don Whitley, Shipley, United Kingdom) at 37°C
in humid containers to minimize evaporation. At 6 time points up to 50 h,
planktonic and biofilm growth was measured. Planktonic suspensions
were transferred into semi-micro cuvettes, and cell density was measured
spectrophotometrically at 630 nm. The remaining biofilm was stained for
60 s with 1% (wt/vol) crystal violet (200 l), which was then removed, and
wells were washed three times with distilled water before allowing plates to
air dry. Biofilm-bound crystal violet was eluted in 100% ethanol (200 l),
and absorbance was measured spectrophotometrically at 600 nm. Biofilm
units (arbitrary units) were calculated by dividing biofilm absorbances by
their corresponding planktonic OD.
Determination of biofilm architecture and viability. Overnight sus-
pensions of S. aureus P0, P10, and x10 were diluted 1 in 40 in MHB (40 ml)
in a Duran bottle containing a partially submerged sterile glass micro-
scope slide. Bottles were incubated at 37°C statically for 24, 48, or 72 h
before gentle rinsing in phosphate-buffered saline (PBS; 50 ml). Biofilm
viability and structure were visualized by fluorescence microscopy.
Briefly, a working solution of BacLight LIVE/DEAD stain (Invitrogen
Ltd., Paisley, United Kingdom) was prepared by adding 1 l each of SYTO
9 (component A) and propidium iodide (component B) to 98 l distilled
water. This solution (20 l) was applied directly to the biofilm and the
slide was covered with a glass coverslip. Slides were incubated at room
temperature in the dark for 15 min, according to the standard BacLight
staining protocol. Biofilms were visualized with an Axioskop 2 fluores-
cence microscope with a 10 objective lens (Carl Zeiss Ltd., Rugby,
United Kingdom), and images were captured using a digital microscope
eyepiece (Cosmos Biomedical, Derbyshire, United Kingdom) and ex-
ported as JPEG files. Bacterial cells incubated in the presence of both stains
fluoresce either green (viable) or red (dead). The excitation and emission
maxima for these dyes are 480 and 500 nm for SYTO 9 and 490 and 635
nm for propidium iodide. The percent viable biomass was determined by
calculating the proportion of red fluorescence as a percentage of total
fluorescence. Biofilm three-dimensional structure was visualized with an
LSM Confocor 2 confocal microscope with a 10 objective lens (Carl
Zeiss Ltd., Rugby, United Kingdom). Images were processed, surface ren-
dered, and quantified using Imaris software (Bitplane AG, Zurich, Swit-
zerland).
Triclosan-Adapted Staphylococcus aureus
June 2012 Volume 56 Number 6 aac.asm.org 3093
 o
n
 January 3, 2017 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Determination of hemolysin activity. The method used for determi-
nation of hemolysin activity was adapted from that of Hathaway and
Marshall (19). Overnight suspensions of S. aureus P0, P10, and 10 were
diluted 1:50 in MHB (50 ml) in a conical flask and incubated with shaking
at 37°C to an optical density at 600 nm of 0.3. Whole defibrinated horse
blood (Oxoid, United Kingdom) was added to a final concentration of 5%
(vol/vol), before incubating for a further 3 h. Negative and positive con-
trols (sterile MHB and distilled water, respectively) were included. Ali-
quots (1 ml) were centrifuged at 16,000  g (1-14 Microfuge; Sigma,
United Kingdom) for 4 min at room temperature, and the absorbance of
the supernatant was measured spectrophotometrically at 540 nm. Colony
counts were performed by plating appropriate dilutions on MSA. To
avoid variation caused by differences in cell number, specific hemolysis
was calculated as the change in the A540 (A540)/CFU.
Determination of DNase activity. The method used for determina-
tion of DNase activity was adapted from the Health Protection Agency
National Standard thermonuclease test method (20). Overnight suspen-
sions of S. aureus P0, P10, and 10 were diluted 1 in 50 in MHB (50 ml)
in a conical flask and incubated with shaking at 37°C to an optical density
at 600 nm of 0.3. Aliquots (1 ml) were incubated at 100°C for 15 min and
centrifuged at 13,000 rpm for 5 min, and supernatants were retained.
Wells were cut into plates containing DNase test agar (Oxoid, United
Kingdom) and filled with supernatant (40 l). Plates were incubated over-
night at 37°C and then overlaid with 1 M HCl. Polymerized DNA makes
the agar opaque, and zones of clearing surrounding the wells indicate
levels of DNase activity. Zone diameters were recorded, and colony counts
were performed by plating appropriate dilutions of unheated cultures on
MSA to account for variations caused by differences in cell number.
Coagulase assay. Suspensions of S. aureus P0, P10, and 10 in Muel-
ler-Hinton broth (1 ml, OD600  0.4) were added to rabbit plasma with
EDTA (3 ml; Bactident coagulase; Merck, Darmstadt, Germany), in trip-
licate, and incubated at 37°C in a water bath. Tubes were monitored for
signs of coagulation over 3 h and scored on a five-point scale according to
the manufacturer’s instructions.
Galleria mellonella pathogenesis assay. The pathogenesis model was
adapted from that of Peleg et al. (42). Final larval-stage G. mellonella (Live
Foods Direct, Sheffield, United Kingdom) was stored in the dark at 4°C for
less than 7 days, before randomly assigning 16 to each treatment group
and incubating at 37°C for 30 min. Overnight suspensions of S. aureus
strains P0, P10, and 10 were washed twice in PBS and diluted appropri-
ately in PBS to achieve an optical density at 600 nm of 0.1 (5  105 to 8 
105 CFU/ml, as confirmed by colony counts on MSA). Aliquots of each
suspension (5 l) were injected into the hemocele of each larva via the last
left proleg using a Hamilton syringe (2.5  103 to 4  103 CFU per
individual). Larvae were incubated in plastic petri dishes at 37°C, and the
number of surviving individuals was recorded daily (dead larvae were
unresponsive to touch and appeared black). An untreated group and a
group injected with sterile PBS were used as negative controls. The exper-
iments were terminated when at least 2 individuals in a control group had
died. Three independent replicates were performed, and significance was
calculated using the log-rank test. Data were plotted as survival curves,
and representative data are presented. Dead individuals were homoge-
nized in sterile PBS and diluted appropriately, and aliquots were spread on
MSA to calculate bacterial load per individual at death.
RESULTS
Triclosan exposure selects for isolates with reduced triclosan
susceptibility. The MIC of triclosan to Staphylococcus aureus
ATCC 6538 (P0) was 0.23 g/ml. After 5 passages (P5), this in-
creased to 9.67 g/ml, and after 10 exposures (P10) it increased to
29 g/ml (a 126-fold increase compared to that for the parent
strain; Fig. 1). Colonies of P10 were markedly smaller than those
of its parent strain (Fig. 2). Further passaging on triclosan-free
medium resulted in a partial reversion of susceptibility and colony
size; following 5 passages on MHA, the MIC was 7.3 g/ml, and
after 10 passages it was 1.1 g/ml. MBC data showed a similar
trend (Fig. 1).
Triclosan-adapted S. aureus grows more slowly than its par-
ent strain in planktonic and biofilm modes. The growth kinetics
of triclosan-adapted S. aureus (P10), its parent strain (P0), and the
strain further passaged on triclosan-free medium (10) were
compared in shaken broth cultures (planktonic growth). As
shown in Fig. 3, P10 underwent an extended lag phase and entered
stationary phase later than P0 and 10. The planktonic growth
kinetics of P0 and 10 were not significantly different. The expo-
nential-phase growth rate of P10 (0.19/h) was less than half that of
P0 (0.43/h) and 10 (0.42/h). Biofilm growth was measured over
50 h using the well-characterized microplate assay (41). Forma-
tion of biofilm by P10 and 10, relative to planktonic growth, was
significantly lower than that by P0 (Fig. 4). Strain 10 formed less
FIG 1 MICs (white bars) and MBCs (black bars) of triclosan to S. aureus ATCC
6538 before exposure (P0), after 5 or 10 passages in the presence of triclosan (P5
and P10, respectively), and after 5 or 10 subsequent passages on triclosan-free
medium (5 and 10, respectively). Error bars show standard deviation (n  6).
FIG 2 Colonies formed on Colombia blood agar by S. aureus parent strain
(P0; a), triclosan-adapted strain (P10; b), and one passaged a further 10 times
on triclosan-free medium (10; c) after aerobic incubation at 37°C for 48 h.
Colonies formed by the triclosan-adapted strain were markedly smaller and
more heterogeneous than those formed by the parent strain.
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biofilm mass than P10 for the first 15 h of growth, after which
levels were not significantly different. Strains P10 and 10 were
also significantly biofilm defective when grown anaerobically
(data not shown). Biofilms formed on glass slides by P0, P10, and
10 differed markedly with respect to aerial coverage (Fig. 5).
Additionally, epifluorescence and confocal microscopy showed
that P0 formed relatively thick three-dimensional microcolony
structures, whereas strains P10 and 10 formed thinner, less
structurally complex biofilms (Fig. 6a). Analysis of representative
images indicated that the density of biomass was markedly higher
in P0 biofilms than in those of P10 or 10 over 72 h (Fig. 6b).
The in vitro hemolytic activity of triclosan-adapted S. aureus
is lower than that of the parent strain. The ability of planktonic
P0, P10, and 10 populations to lyse erythrocytes was investi-
gated. Higher absorbance readings are indicative of lysis and re-
lease of hemoglobin into the supernatant. Hemolysis by P10 was,
on average, 2% of the P0 value, a statistically significant difference
(P  0.01; Fig. 7). Although 10 showed a partial reversion of
hemolytic activity, it was still significantly lower than that of the
parent strain (5% of the P0 value).
The in vitro DNase activity of triclosan-adapted S. aureus is
lower than that of the parent strain. The levels of thermostable
DNase produced by planktonic P0, P10, and 10 populations
were investigated with an agar diffusion test. Zones of clearing
after addition of heated culture supernatant indicate DNase activ-
ity. Activity (mean zone diameter, 9.47  0.53 cm) was observed
only surrounding wells filled with culture supernatant from the P0
strain. No DNase activity was observed surrounding wells filled
with culture supernatants from the P10 or 10 strain (see Table
2). Cell density in the P0 cultures (4.6  108 CFU/ml) was not
significantly different from that in the P10 or 10 populations
(P  0.2).
The in vitro coagulase activity of triclosan-adapted S. aureus
is lower than that of the parent strain. The levels of coagulase
produced by planktonic P0, P10, and 10 populations were investi-
gated using a standard tube coagulase test. Coagulase activity was
observed in all strains. Although strain P0 displayed a positive result
after 30 min, significant coagulation was delayed in strains P10 and
10, with both showing a positive result after 2 h (Table 1).
Supplementation with hemin, menadione, or thymidine
does not restore a non-SCV phenotype. To ascertain whether the
FIG 3 Planktonic growth of S. aureus parent strain (P0; triangles), triclosan-
exposed strain (P10; squares), and one passaged a further 10 times on tri-
closan-free medium (10; circles). P10 exhibited an extended lag phase,
slower growth, and a delayed stationary phase compared to P0. Error bars
show standard deviation (n  3).
FIG 4 Biofilm growth of S. aureus parent strain (P0; triangles), triclosan-
exposed strain (P10; squares), and one passaged a further 10 times on tri-
closan-free medium (10; circles) on polystyrene. Data are shown as biofilm
units. A biofilm unit is defined as the absorbance of the biofilm-bound crystal
violet divided by the corresponding planktonic OD and corrects the data to
give a representation of biofilm formation irrespective of planktonic mass.
Biofilm formation by P10 was markedly lower than that by P0. This difference
was significant at all time points from 6 h (P  0.001; n  12).
FIG 5 Biofilm growth on glass of S. aureus parent strain (P0), triclosan-ex-
posed strain (P10), and one passaged a further 10 times on triclosan-free me-
dium (10) as viewed by epifluorescence microscopy. Green fluorescence
represents viable cells, and red fluorescence represents nonviable cells. Repre-
sentative fields of view at 24 h are shown.
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SCV phenotype was caused by mutations affecting biosynthesis of
hemin, menadione, or thymidine, MHA containing these mole-
cules was inoculated with P10. The concentrations used were
based on the previous reports that maximal restoration of normal
phenotypes occurred with 1.0 M hemin, 0.375 M menadione,
or 6.2 M thymidine (9, 56). Further plates were inoculated with
P0 and 10 to control any growth-inhibitory effects of medium
supplementation. No supplementation affected the colony mor-
phologies of any strain (Table 2), suggesting that the phenotype of
P10 is not attributable to defects in hemin, menadione, or thymi-
dine biosynthesis.
Triclosan-adapted S. aureus is less virulent in an inverte-
brate model. The Galleria mellonella pathogenesis assay was used
to assess the relative virulence of the test strains. Groups of larvae
were injected with P0, P10, or 10 and incubated at 37°C. Dead
individuals were recorded daily, and data were plotted as survival
curves (Fig. 8a). Over 6 days of incubation, the P10 treatment
group suffered the fewest deaths, whereas survival in the group
inoculated with the parent strain P0 fell rapidly, leveling out at 5
individuals in the example shown. In comparison, 10 displayed
moderate virulence, suggesting a partial reversion in phenotype. A
log-rank test including all replicates showed that all three treat-
ment groups were significantly different (n  48). Within 24 h of
death, the bacterial load of each individual was measured. Al-
though numbers varied markedly between individuals (107 to
1011), there was no significant difference between treatment
groups (Fig. 8b). Colony morphologies of bacteria recovered from
dead larvae were similar to the morphology of the inoculum in all
groups, suggesting that the SCV-like strain did not revert to wild
type, or vice versa, during infection. Results have been summa-
rized in Table 2.
DISCUSSION
S. aureus is known to generate phenotypically distinct subpopula-
tions termed small-colony variants (SCVs), which have occasion-
ally been isolated from patients with chronic and relapsing infec-
FIG 6 Biofilm growth on glass of S. aureus parent strain (P0), triclosan-exposed strain (P10), and one passaged a further 10 times on triclosan-free medium
(10) as viewed by confocal microscopy. Specialist software was used to surface render the images, allowing comparison of relative density and structure (a) and
measurement of biomass density (b). Representative images and data are shown (P0, black bars; P10, white bars; 10, striped bars).
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tions. Clinically occurring SCVs commonly result from hemin,
menadione, or thymidine auxotrophy but may also result from
mutations in other genes (47). SCV-like variants can arise in re-
sponse to sublethal exposure to aminoglycoside antibiotics (13)
and the biocide triclosan. Thus, concerns have been expressed that
exposure of S. aureus to triclosan might lead to the emergence of S.
aureus SCVs with reduced susceptibility to antimicrobials (7).
However, care must be taken when extrapolating clinical rele-
vance from in vitro data. The fact that triclosan is normally applied
topically at concentrations considerably higher than those used to
generate SCVs should be taken into account (48), as should the
fact that although elevated (0.0029%, wt/vol), the MICs for tri-
closan in the adapted strains described in the current study re-
mained orders of magnitude lower than the triclosan concentra-
tions in washes used to control MRSA in hospitals (0.3 to 1.0%,
wt/vol) (11, 57). Little is known about the physiology and patho-
genicity of triclosan-induced SCVs, and doubts concerning their
ability to initiate infection in healthy individuals have been raised
(48).
There have been conflicting reports concerning the virulence
of SCVs, whether of clinical origin or created in the laboratory. For
example, a hemB mutant was more virulent than its parent strain
in a murine septic arthritis model (23) but demonstrated no sig-
nificant difference in virulence in a rabbit endocarditis model (6).
Another report suggested that hemB and menD mutants and SCVs
of clinical origin were reduced in virulence (50). Clinically isolated
SCVs may, however, be physiologically distinct from hem and men
mutants generated in the laboratory, and in this respect, recent
proteomic analyses revealed significant differences in protein ex-
pression between a hemB mutant, a gentamicin-induced SCV, and
a clinical SCV isolate (29). Markedly increased expression of gly-
colytic and pyruvate dehydrogenase enzymes was detected in the
laboratory mutant and gentamicin-induced strains compared to
the clinical isolate. However, there has previously been little infor-
mation available to indicate whether strains selected by triclosan
exposure vary in virulence compared to the progenitor strains.
The current investigation has demonstrated that repeated ex-
posure of S. aureus to triclosan can result in a phenotype with
marked similarities to SCVs but that is attenuated in biofilm for-
mation capacity, hemolysis, DNase, coagulase activities, and
pathogenesis in an animal model (Table 2). This suggests that
while repeated exposure to triclosan may result in an SCV-like
phenotype, this is not necessarily associated with increases in vari-
ables associated with pathogenicity.
Serial exposure of bacteria to concentration gradients of anti-
microbials in agar is a highly selective procedure that has been
validated as an effective method for selecting isolates with de-
creased susceptibility (35). The G. mellonella infection model has
previously been used to study bacterial pathogenesis (5, 22, 39),
including antimicrobial insusceptibility in S. aureus (42). Data
generated with this model in the current study showed a clear
distinction between the virulence of strains P0, P10, and 10.
Benefits of G. mellonella over other nonmammalian systems such
as Caenorhabditis elegans include the fact that individual animals
may be injected with a defined inoculum, individual animals can
be maintained at human body temperature, and the system has
been shown to broadly reflect virulence patterns seen in mamma-
lian systems (22).
With respect to specific virulence factors, DNase activity was
markedly reduced following triclosan exposure. It has been sug-
gested that staphylococcal DNase interferes with the antimicrobial
activity of neutrophil-produced extracellular traps (NETs)
through the breakdown of the chromatin backbone. DNase-me-
diated NET degradation has been demonstrated for S. aureus in a
murine model, in which mice infected with wild-type S. aureus
TABLE 2 Summary indicating presence or absence of tested
characteristics in strains P0, P10, and 10
Characteristic
Result for strain:
P0 P10 10
MIC (g/ml) to triclosan 0.23 29 1.1
Slow planktonic growth   
Impaired biofilm growth   
Impaired DNase activity   
Impaired hemolytic activity   
Delayed coagulase activity   
Impaired virulence   
Reversal by hemin supplementation   
Reversal by menadione supplementation   
Reversal by thymidine supplementation   
FIG 7 Hemolytic activity of S. aureus parent strain (P0; black bar), triclosan-
exposed strain (P10; white bar), and one passaged a further 10 times on tri-
closan-free medium (10; striped bar). Whole blood (final concentration,
5%, vol/vol) was added to pre-stationary-phase cultures, and free hemoglobin
from lysed erythrocytes was measured spectrophotometrically at 450 nm. Data
are expressed as mean percentages of the mean P0 value. Error bars show
standard deviation (n  3).
TABLE 1 Coagulase activity of S. aureus parent strain (P0), a triclosan-
adapted strain (P10), and one passaged a further 10 times on triclosan-
free medium (10)
Time (h)
Activity for straina:
P0 P10 10
0.5   
1   
2   
3   
a Tubes were monitored for signs of coagulation over 3 h and scored on a five-point
scale according to the manufacturer’s instructions. , no coagulase detected; , small
separate clots (negative); , small joined clots (negative); , extensively
coagulated clots (positive); , complete coagulation (positive) (Bactident
coagulase; Merck, Darmstadt, Germany).
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exhibited a significantly higher mortality rate than those infected
with the nuclease-deficient mutant (8). Host extracellular DNA
(eDNA) in G. mellonella reportedly plays a similar role in the
immune response as it does in humans (3), suggesting that a re-
duction in DNase activity might partially account for the reduced
virulence of the S. aureus SCV observed in our G. mellonella assay.
Importantly, S. aureus became markedly defective in its ability
to form biofilms following triclosan adaptation. Strains P10 and
10 formed biofilm less readily than the parent strain on polysty-
rene over 50-h incubations, and biofilms grown on glass were less
dense, exhibiting simpler architecture than the parent strain. To
our knowledge, there are currently no data in the literature con-
FIG 8 Example survival curve showing virulence of S. aureus parent strain (P0), triclosan-exposed strain (P10), and one passaged a further 10 times on
triclosan-free medium (10) in a G. mellonella survival assay (a; n  16) and bacterial load at death (b; each point corresponds to the bacterial load in an
individual animal). P0 caused significantly higher death rates than both other strains, whereas the virulence of 10 was not fully restored. Untreated and
PBS-treated control data are also shown. Although the bacterial load recovered from dead larvae varied, there was no significant difference between treatment
groups. Example images of treatment groups are also shown.
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cerning the ability of triclosan-selected SCVs to form biofilms,
and data on other SCVs otherwise generated have not been con-
clusive; for example, S. aureus SCVs created by exposure to ami-
kacin formed greater biofilm mass on polystyrene (52) but not on
glass (51), and a Staphylococcus epidermidis SCV formed by a mu-
tation in hemB was almost entirely biofilm defective at 24 h but,
contrary to findings presented in the current study, reverted to
levels approximating those of the wild type at 48 h (1). However,
since the authors did not measure biofilm relative to planktonic
growth, this may be a reflection of the inherently slow growth of
the SCV phenotype, rather than a specific measure of biofilm-
forming capability. In the current study, biofilm formation on
polystyrene was measured quantitatively over 50 h, and these data
were then converted to relative biofilm-forming units (absor-
bance of the biofilm-bound crystal violet divided by the corre-
sponding planktonic OD) and therefore reflect biofilm formation,
irrespective of planktonic bacterial productivity. Since initial at-
tachment does not appear to be impaired and biofilm deficiency is
not due solely to reduced growth rate, strains P10 and 10 appear
to be specifically deficient in biofilm maturation. This is poten-
tially a consequence of repression of the intercellular polysaccha-
rides or protein PIA or Aap, respectively. The staphylococcal ac-
cessory regulator gene sarA, which controls several virulence
determinants, including biofilm formation, hemolysins, and
DNase, may also be implicated. Furthermore, recent analysis has
shown that an increase in DNase production resulting from a
mutation in the stress response factor sigB inhibited biofilm
growth by breaking down eDNA (27). Although this appears to be
in contrast to data presented in the current investigation, there is
much to learn about the role of eDNA in such a multifactorial
process as biofilm formation. Importantly, since S. aureus infec-
tions related to medical devices are strongly associated with bio-
film formation (17), the selection for biofilm-deficient strains may
be clinically advantageous since biofilms are markedly less suscep-
tible to antimicrobial therapy than their planktonic counterparts
(34, 40), a phenomenon that is due to biofilm-specific physiology
as well as diffusion resistance (33). Therefore, the inability to form
biofilm could potentially outweigh changes in susceptibility re-
lated to the SCV phenotype. Further, despite a raised MIC to a
single biocide, an inability to form biofilm may leave such SCVs
vulnerable to a wide range of antimicrobial and immunological
challenges.
Although the phenotype of the triclosan-adapted strain (P10)
was practically identical to that of the previously described SCVs
in terms of colony size and planktonic growth, initial supplemen-
tation data indicated that P10 was not an electron transport chain-
defective SCV. It is, however, possible that mechanisms other than
auxotrophy to hemin, menadione, or thymidine were responsible
for the induction of an SCV-like response in this strain.
S. aureus generated from 10 further passages on triclosan-free
medium (10) showed reversion in planktonic growth rate and,
to a lesser extent, in colony diameter. Only minor reversions in
hemolytic activity and biofilm formation were observed, and like
P10, no DNase activity was detected. Strain 10 was significantly
less pathogenic than the parent strain in the G. mellonella model
and exhibited a marked increase in triclosan susceptibility. Fur-
thermore, P10 did not revert to normal colony size in vivo during
the course of the infection model (data not shown).
In conclusion, we have shown that while repeated exposure to
triclosan might select for S. aureus strains with decreased suscep-
tibility to triclosan, this may be associated with deficiencies in
growth and virulence.
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